COVID-19-associated coagulopathy and disseminated intravascular coagulation.
Int J Hematol
; 113(1): 45-57, 2021 Jan.
Article
in English
| MEDLINE | ID: covidwho-1064611
ABSTRACT
The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms. The most frequently reported coagulation/fibrinolytic abnormality in COVID-19 is the increase in D-dimer, and its relationship with prognosis has been discussed. However, limits exist to the utility of evaluation by D-dimer alone. In addition, since the coagulation/fibrinolytic condition sometimes fluctuates within a short period of time, regular examinations in recognition of the significance of the examination are desirable. The pathophysiology of disseminated intravascular coagulation (DIC) associated with COVID-19 is very different from that of septic DIC, and both thrombotic and hemorrhagic pathologies should be noted. COVID-19 thrombosis includes macro- and microthrombosis, with diagnosis of the latter depending on markers of coagulation and fibrinolysis. Treatment of COVID-19 is classified into antiviral treatment, cytokine storm treatment, and thrombosis treatment. Rather than providing uniform treatment, the treatment method most suitable for the severity and stage should be selected. Combination therapy with heparin and nafamostat is expected to develop in the future. Fibrinolytic therapy and adsorption therapy require further study.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Blood Coagulation Disorders
/
Pandemics
/
SARS-CoV-2
/
COVID-19
Type of study:
Case report
/
Experimental Studies
/
Prognostic study
Topics:
Long Covid
Language:
English
Journal:
Int J Hematol
Journal subject:
Hematology
Year:
2021
Document Type:
Article
Affiliation country:
S12185-020-03029-y
Similar
MEDLINE
...
LILACS
LIS